Patients: This phase 2 study involved 14 women with metastatic breast cancer. The median age was 60.5, ranging from 37 to 89 years of age. Most (12) had previously received chemotherapy for their breast cancer.
Treatment: These women were treated with vorinostat (suberoylanilide hydroxamic acid). Vorinostat is a small molecule that inhibits the action of certain proteins called HDAC enzymes.
Toxicity: Two grade 4 toxicities occurred, mucositis and lymphopenia. Grade 3 fatigue, nausea/vomiting, dehydration, hypokalemia, and thrombocytopenia were each reported in one patient.
Results: The median overall survival was 24 months.
DISCLAIMER: The following is a summary of some of the terms & conditions for accessing the information on this website. It is provided for convenience only. For the full terms & conditions please click here. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional medical advice, examination, diagnosis or treatment. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. This website provides links to other websites for convenience only. Cancer Monthly is not responsible for the availability or content of these external websites, nor does Cancer Monthly endorse, warrant or guarantee the products, services or information described or offered at these other websites.